The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

John G. McHutchison

Duke Clinical Research Institute and Division of Gastroenterology

Duke University Medical Center

Durham

North Carolina 27715

USA

[email]@mc.duke.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27715, USA. 2002 - 2010
  • ALT (Alliance for Liver Therapy) Group, Division of Gastroenterology & Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, USA. 2004 - 2008

References

  1. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. McHutchison, J., Goodman, Z., Patel, K., Makhlouf, H., Rodriguez-Torres, M., Shiffman, M., Rockey, D., Husa, P., Chuang, W.L., Levine, R., Jonas, M., Theodore, D., Brigandi, R., Webster, A., Schultz, M., Watson, H., Stancil, B., Gardner, S. Gastroenterology (2010) [Pubmed]
  2. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. McHutchison, J.G., Lawitz, E.J., Shiffman, M.L., Muir, A.J., Galler, G.W., McCone, J., Nyberg, L.M., Lee, W.M., Ghalib, R.H., Schiff, E.R., Galati, J.S., Bacon, B.R., Davis, M.N., Mukhopadhyay, P., Koury, K., Noviello, S., Pedicone, L.D., Brass, C.A., Albrecht, J.K., Sulkowski, M.S. N. Engl. J. Med. (2009) [Pubmed]
  3. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., Muir, A.J. N. Engl. J. Med. (2009) [Pubmed]
  4. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison, J., Sulkowski, M. J. Viral Hepat. (2008) [Pubmed]
  5. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. McHutchison, J.G., Patel, K., Schiff, E.R., Gitlin, N., Mur, R.E., Everson, G.T., Carithers, R.L., Davis, G.L., Marcellin, P., Shiffman, M.L., Harvey, J., Albrecht, J.K. Aliment. Pharmacol. Ther. (2008) [Pubmed]
  6. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. McHutchison, J.G., Bacon, B.R., Gordon, S.C., Lawitz, E., Shiffman, M., Afdhal, N.H., Jacobson, I.M., Muir, A., Al-Adhami, M., Morris, M.L., Lekstrom-Himes, J.A., Efler, S.M., Davis, H.L. Hepatology (2007) [Pubmed]
  7. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. McHutchison, J.G., Dusheiko, G., Shiffman, M.L., Rodriguez-Torres, M., Sigal, S., Bourliere, M., Berg, T., Gordon, S.C., Campbell, F.M., Theodore, D., Blackman, N., Jenkins, J., Afdhal, N.H. N. Engl. J. Med. (2007) [Pubmed]
  8. Making it happen: managed care considerations in vanquishing hepatitis C. McHutchison, J.G., Bacon, B.R., Owens, G.S. Am. J. Manag. Care (2007) [Pubmed]
  9. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. McHutchison, J.G., Patel, K., Pockros, P., Nyberg, L., Pianko, S., Yu, R.Z., Dorr, F.A., Kwoh, T.J. J. Hepatol. (2006) [Pubmed]
  10. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. McHutchison, J.G., Bartenschlager, R., Patel, K., Pawlotsky, J.M. J. Hepatol. (2006) [Pubmed]
  11. Definition and management of anemia in patients infected with hepatitis C virus. McHutchison, J.G., Manns, M.P., Longo, D.L. Liver Int. (2006) [Pubmed]
  12. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. McHutchison, J., Poynard, T., Afdhal, N. Clin. Gastroenterol. Hepatol. (2006) [Pubmed]
  13. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. McHutchison, J.G., Shiffman, M.L., Cheung, R.C., Gordon, S.C., Wright, T.L., Pottage, J.C., McNair, L., Ette, E., Moseley, S., Alam, J. Antivir. Ther. (Lond.) (2005) [Pubmed]
  14. Chronic hepatitis C: an age wave of disease burden. McHutchison, J.G., Bacon, B.R. Am. J. Manag. Care (2005) [Pubmed]
  15. Future trends in managing hepatitis C. McHutchison, J.G., Dev, A.T. Gastroenterol. Clin. North Am. (2004) [Pubmed]
  16. Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfected with HIV?. McHutchison, J., Zekry, A. Nature Clinical Practice. Gastroenterology & Hepatology (2004) [Pubmed]
  17. Future therapy of hepatitis C. McHutchison, J.G., Patel, K. Hepatology (2002) [Pubmed]
 
WikiGenes - Universities